

Date: 29 November 2017

Sydney, Australia

ASX Limited 20 Bridge Street SYDNEY NSW 2000

Noxopharm Limited

ASX: NOX

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia

Operational Office:

Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia

Board of Directors Mr Peter Marks

Chairman Non-Executive Director

Dr Graham Kelly

Chief Executive Officer Managing Director

Dr lan Dixon Non-Executive Director

Webcast of Noxopharm Limited 2017 Annual General Meeting

Noxopharm Limited (ASX: NOX), an Australian oncology drug development company, invites shareholders and the market to visit the following link;

http://www.noxopharm.com/irm/content/presentations.aspx?RID=401

for the webcast recording of the 2017 AGM Presentations.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of chemotherapy- and radiation-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.

About Nyrada Inc.

Nyrada Inc is a recently formed, New York-based biotechnology company established to house Noxopharm non-oncology drug assets.

Investor & Corporate Enquiries:	Company Secretary:
Prue Kelly	David Franks
M: 0459 022 445	T: +61 2 9299 9690
E: info@noxopharm.com	E: <u>dfranks@fa.com.au</u>

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and

assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.